Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 6/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 6/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 6/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 6/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 1.00 |
| ▸ | GSAP | A4D1B5 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 5/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.59 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.59 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353214 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL453583 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12462877 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14418092 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2685774 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL453584 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29359226 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4413288 | 0.96 | PSEN1 (0.92) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4413442 | 0.94 | PSEN1 (0.89) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4985301 | 0.93 | PSEN1 (0.88) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160950-B2 | Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-12-25 | — | — | US | claimed |
| US-20150335614-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | PHOLORONOL INC (US) | 2015-11-26 | — | — | US | claimed |
| US-8883502-B2 | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-11 | — | — | US | claimed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | claimed |
| US-20130196976-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | Phloronol, Inc. (US) | 2013-08-01 | — | — | US | claimed |
| US-8377886-B2 | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-02-19 | — | — | US | claimed |
| WO-2012067305-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING β-SECRETASE INHIBITOR | PHLORONOL, LNC (US) | 2012-05-24 | — | — | WO | claimed |
| US-20120122822-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | Phloronol, Inc. (US) | 2012-05-17 | — | — | US | claimed |
| US-8173423-B2 | Diagnosis and treatment of T-cell acute lymphoblastic leukemia | VIB VZW (BE) | 2012-05-08 | — | — | US | claimed |
| WO-2012050370-A2 | COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS CONTAINING A GAMMA SECRETASE INHIBITOR AS AN ACTIVE INGREDIENT | 성균관대학교산학협력단 (KR) | 2012-04-19 | — | — | WO | claimed |
| US-20100130586-A1 | DIAGNOSIS AND TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | VIB VZW (BE) | 2010-05-27 | — | — | US | claimed |
| US-12584111-B2 | Compositions and methods for long term culture of hepatocytes | PEKING UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250354113-A1 | INNER EAR ORGANOIDS HAVING IMPROVED HAIR CELL DIFFERENTIATION ABILITY AND METHOD FOR PRODUCING SAME | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-11-20 | — | — | US | disclosed |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20100130586-A1 | DIAGNOSIS AND TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | VIB VZW (BE) | 2010-05-27 | — | — | US | disclosed |
| WO-2010002955-A2 | STEMNESS SIGNATURE BIOMARKERS AND METHODS OF USE | MERCK & CO., INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2092080-A1 | DIAGNOSIS AND TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | VIB VZW (BE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009035522-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DISEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008055924-A1 | DIAGNOSIS AND TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | VIB VZW (BE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | GSK3B, GSKIP, BACE1 | PSEN1 21/4885PSEN2 36/4885APH1B 78/4885 |
| US-12584111-B2 | Compositions and methods for long term culture of hepatocytes | WNT3A, CTNNB1, WNT1 | PSEN1 890/4885PSEN2 821/4885APH1B 80/4885 |
| US-20130196976-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | BACE1, BACE2, APP | PSEN1 5/4885PSEN2 8/4885APH1B 7/4885 |
| US-20120122822-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | BACE1, BACE2, APP | PSEN1 5/4885PSEN2 8/4885APH1B 7/4885 |
| US-20150335614-A1 | COMPOSITIONS FOR REDUCING BETA-AMYLOID-INDUCED NEUROTOXICITY COMPRISING BETA-SECRETASE INHIBITOR | BACE1, BACE2, APP | PSEN1 5/4885PSEN2 8/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.